Wheat-free Diet in the Treatment of Sjogren's Syndrome

NCT ID: NCT05644795

Last Updated: 2025-03-30

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-01
• Study Completion Date: 2026-01-30

Brief Summary

Recent data show that some foods can increase intestinal mucosa permeability and immune activation of subjects with gastrointestinal (GI) symptoms. Wheat seems the most frequent food which activates this inflammatory response and can cause both GI and extra-intestinal symptoms. Patients suffering from wheat-related troubles, in absence of celiac disease diagnosis, can suffer from non-celiac wheat sensitivity (NCWS) and our previous studies showed that about 25% of them are also affected by autoimmune diseases (AD). A gluten-free diet (GFD) can influence inflammatory pattern of AD, including Sjogren's syndrome (SS). Thus, the investigators would enquire if SS patients may also suffer from NCWS and how a wheat-free diet (WFD) modifies their clinical features, and inflammatory and cytokine pattern. The investigators will also assess how wheat reintroduction, by an open challenge, modifies their clinical parameters, intestinal permeability, and both local and systemic inflammatory response.

Detailed Description

In recent years, the existence of a wheat-related disorder, in patients who do not suffer from celiac disease (CD) or wheat allergy (WA), has been definitively ascertained and defined as non-celiac wheat sensitivity (NCWS). Its prevalence in the general population is unknown but self-reported NCWS is around 10%. Conflicting data have been reported about the underlying physiopathology. It has been known for years how exposure to gliadin, both in CD and in healthy patients (albeit with reduced levels in the latter), is able to alter intestinal permeability acting on zonulin release and signalling mechanisms. More recently, it has been shown that wheat has high concentrations of wheat amylase-trypsin inhibitors (ATIs), proteins able to activate innate immunity via toll-like receptor-4 (TLR-4) on myeloid cells. Orally ingested ATIs increase intestinal inflammation by activating gut and mesenteric lymphnode myeloid cells.

An increasing number of data have shown that patients with NCWS could have an association with autoimmune diseases, including thyroiditis, undifferentiated connective tissue disease, psoriatic arthritis, spondylarthritis, and Sjogren's syndrome (SS).

SS is an autoimmune disease characterized by an infiltrate of mononuclear cells, mainly lymphocytes, in the exocrine glands, especially the salivary and lacrimal glands. Some preliminary data suggested that a GFD can reduce sialadenitis and increase salivary flow in SS and CD patients. Furthermore, some SS patients have an inflammatory response (release of nitric oxide) to a rectal gluten challenge.

Based on these evidences, as well as on the ability of gluten/wheat to increase intestinal permeability, altering zonulin mechanisms of regulation and signalling, and the ability of some of its components (ATIs, but not only) to activate a local inflammatory response, it could be hypothesized that gluten/wheat may represents one of the pathogenetic environmental factors of SS and that its intake may be able to worsen symptoms in affected patients. In our hypothesis, exposure to gluten/wheat would cause a release of zonulin, which, binding to the surface of the intestinal epithelial cells, is able to modify cell cytoskeleton and to cause the loss of normal occludins function, ultimately leading to an increased monolayer permeability. This increase in permeability would result in greater exposure of the immune system cells to gluten/wheat molecules via activation of TLR-4, with an increase in the infiltration and activation of myeloid cells in the intestinal mucosa and an augmented activity of lymphnode dendritic cells. Such local inflammatory response would have systemic repercussions with alteration of normal cytokine pattern and infiltration of monocytes/macrophages and T cells in the salivary and lacrimal glands, thus being able to contribute, as an environmental factor, to the onset and exacerbation of the clinical manifestations of SS.

Therefore, the investigators hypothesize that a wheat-free diet (WFD) can reduce the inflammatory state and ameliorate the clinical symptoms in SS patients. This hypothesis will be evaluated in both SS patients with associate GI symptoms and in those without GI symptoms. The successive clinical and immunologic reaction to the re-exposure to wheat ingestion, performed by an open challenge, will be also evaluated to confirm a wheat-dependent mechanism and to understand the underlining mechanisms. The project results will provide data about a possible therapeutic role of a WFD in SS and will improve the knowledges about the axis between the intestinal permeability and the systemic inflammation in SS.

More specifically, the investigators aim to:

• identify the prevalence of self-reported NCWS in SS patients;
• assess the overall effect that a WFD plus cow's milk products free diet (CMPFD) determines in symptoms control of the patients affected with SS; the investigators decided to include a CMPFD in association with a WFD because, according to several authors, including our previous studies, NCWS, and more generally gluten-related disorders, are often associated with multiple foods intolerance, first of all cow's milk products intolerance;
• evaluate, by an open wheat challenge, the real frequency of a coexistent NCWS condition;
• assess the possible role played by wheat ingestion in the pathogenesis and molecular mechanisms of SS and NCWS by analysing the variation of intestinal permeability and gut microbiota, in association with cytokines and lymphocytes pattern typical of SS.

Conditions

Sjogren's Syndrome; Non-celiac Gluten Sensitivity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Active Comparator: wheat/milk free diet (W/MFD) group

Patients randomized to intervention group will go to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.

Group Type: ACTIVE_COMPARATOR

Wheat/milk free diet (W/MFD) group

Intervention Type: DIETARY_SUPPLEMENT

Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.

Placebo Comparator: rice/turkey free diet (R/TFD) group

Patients randomized to control group will go to a 2 months elimination diet (rice and turkey's meat). After 2 months of elimination diet they will crossover to a 2 months elimination diet (wheat and cow's milk products). After 2 months of elimination diet they will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify, patients will end the study.

Group Type: PLACEBO_COMPARATOR

Rice/turkey free diet (R/TFD) group

Intervention Type: DIETARY_SUPPLEMENT

Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.

Interventions

Wheat/milk free diet (W/MFD) group

Patients randomized to intervention diet group will have to follow a wheat and cow's milk products free diet and, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.

Intervention Type: DIETARY_SUPPLEMENT

Rice/turkey free diet (R/TFD) group

Patients randomized to control diet group will have to follow a diet with elimination of rice and turkey's meat products for 2 months; after that they will crossover to a wheat and cow's milk products free diet and, finally, after 2 months, they will be exposed to an open wheat challenge, with reintroduction of wheat. After 2 weeks of open diet, or whenever dermatologic, intestinal and/or extraintestinal symptoms should return or intensify, all patients will be revaluated and will end the study.

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

Intervention Group; Control Group

Eligibility Criteria

Inclusion Criteria

• age >18 and <65 years;
• negativity of anti-deamidated gliadin protein (anti-DGP) immunoglobulins (Ig) class A (IgA) and immunoglobulins (Ig)G, anti-tissue transglutaminase (anti-tTG) class IgA and IgG, and Endomysium antibodies (EmA);
• absence of intestinal villous atrophy, documented in all the patients carrying the DQ2 and/or the DQ8 Human Leukocyte Antigen (HLA) haplotypes (thus irrespective of CD-specific serum antibody negativity
• absence of WA (negative prick-test and/or specific serum immunoglobulin (Ig) E assay for wheat, gluten, and gliadin).

Exclusion Criteria

• age <18 and >65 years;
• self-exclusion of gluten/wheat from the diet and refusal to reintroduce it, for diagnostic purposes, before entering the study;
• pregnancy;
• alcohol and/or drug abuse;
• Helicobacter pylori and other bacterial and/or parasitic infections;
• diagnosis of chronic inflammatory bowel disease and other organic pathology affecting the digestive system (e.g., severe liver disease), nervous system diseases, major psychiatric disorders, immunological deficits, and impairments that limit physical activity;
• diagnosis of cancer
• patients undergoing chemotherapy and/or radiotherapy.

Study design In a preliminary phase of the study, all patients who access the SS outpatient clinic of the Rheumatology Department of the University Hospital 'P. Giaccone' of Palermo, Italy, will be asked to answer, consecutively, to a questionnaire for the self-assessment of wheat and other foods' intolerance.

After this evaluation, individual's enrollment will start. A database will be predisposed to register demographic, clinical, laboratory, cytofluorimetric and immunohistochemistry data. A repository bank will be used to collect samples from patients at different timepoints.

Before starting the elimination diet (at time 0, T0), patients will be evaluated by experienced rheumatologists to assess their clinical features, as well as by physicians with expertise in the field of food intolerance about GI and extraintestinal symptoms which could be related to foods intake. Moreover, at this time point, all subjects will be subjected to:

• salivary flux study, by standard sialometry, and salivary samples collection (treated to block enzymatic digestion of proteins), to dose immunologic and inflammatory markers;
• a blood sample, for the analysis of inflammatory markers, cytokine profile, and intestinal permeability markers;
• a urine collection, after the administration of the lactulose/mannitol (LA/MA) test, to define intestinal permeability;
• a collection of stools, for calprotectin assay and definition of the gut microbiota;
• a dietary consult to better explain the dietary approach and provide any information useful to allow adherence to the elimination diet;
• finally, an alimentary (for the self-assessment of adherence to the diet) and symptom's diary will be provided to all patients, which must be filled-in daily.

After 2 months of elimination diet (at time 1, T1), intervention and control patients will be evaluated again both clinically and by laboratory techniques, repeating exactly what have been done at T0. Moreover, they will have to deliver alimentary and symptom's diary, and will discuss the results with physicians.

At this time-point, the subjects enrolled in the intervention group will go to an open challenge, with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify (T2int), patients will be valued again both clinically and by laboratory techniques, repeating exactly what have been done at T0 and T1. Patients in this group will end the study at this time-point.

At the same timepoint, patients enrolled in the control group will be asked to repeat the elimination diet, this time removing from the diet wheat and all cow's milk (both fresh and aged) products (i.e., i.e., WFD plus CMPFD, in the context of a cross-over design), for further 2 months (T2con). At the end of these 2 months patients will be valued again both clinically and by laboratory techniques repeating exactly what have been done at T0 and T1. As described before for the intervention group, at this time-point patients of the control group will go to an open challenge with reintroduction of wheat. After 2 weeks of open diet or whenever rheumatologic, intestinal and/or extraintestinal symptoms should return or intensify (T3con), patients will be valued again both clinically and by laboratory techniques repeating exactly what have been done at T0, T1 and T2con. Patients in this group will end the study at this time-point.

Sample size The sample size is difficult to determine as no precise data are known about the effectiveness of a WFD and the response to wheat re-exposure after challenge in SS patients, as well as NCWS frequency in these subjects; previously reported data suggest that about 25% of NCWS patients suffer from an autoimmune disease, and in a study evaluating the effect of a GFD on quality of life, GI symptoms, and immune system in patients with fibromyalgia and NCWS, statistical significance was reached with 10 subjects. Other studies assessing NCWS immunological pattern obtained statistical significance with 26, 30, 22, and 12 patients. Therefore, considering the nature of this prospective and pilot study the investigators planned to enroll a total of 30 patients suffering from SS, 15 with GI symptoms and 15 without, fulfilling the American-European Consensus Group criteria for SS.

Definition of 'positivity' to the open challenge During the open challenge period, patients will be asked to note the possible onset of intestinal and/or extraintestinal symptoms using the food and symptom's diary, using a 10-point Visual Analogic Scale (VAS). The challenges will be stopped when a clinical reaction will occur for at least two consecutive days with a >3-point increase in the patient's recorded symptom VAS scale. The challenges will be considered positive if the same symptoms, which were initially present, will reappear after their disappearance on elimination diet and if the GSRS score and/or the extraintestinal symptoms rating scale will be 25% higher than the same score recorded on elimination diet. Finally, from a strictly rheumatologic point of view, the challenge will be considered positive if a 5% increase in the ESSPRI and ESSDAI score will be registered compared to the same score recorded on the elimination diet.

Statistical Analysis Statistical analysis will be performed using commercial software. Parametric and non-parametric statistical analysis will be performed calculating the mean ± standard deviation (SD) and median, respectively. For comparison of parametric and non-parametric data, the t-test and Mann-Whitney rank-sum test will be used where appropriate. Spearman's correlation analysis will be used to quantify the association between analysed variables. Data will be expressed as mean ± SD. P values less than 0.05 will be considered significant.

All subjects will agree to participate in the study. The study protocol will conform to the ethical guidelines of the Declaration of Helsinki, will be preliminary approved by the Human Research committee of the University Hospital of Palermo, Italy, and registered on the CliniaclTrials.gov. All authors will have access to the study data and will review and approve the final manuscript.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aurelio Seidita

UNKNOWN

Sponsor Role: collaborator

University of Palermo

OTHER

Sponsor Role: lead

Responsible Party

Pasquale Mansueto

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Antonio Carroccio, MD

Role: STUDY_CHAIR

University of Palermo

Giuliana Guggino, MD

Role: STUDY_CHAIR

University of Palermo

Locations

Internal Medicine Department of the University Hospital of Palermo

Palermo, Palermo, Italy

Site Status: RECRUITING

Rheumatology Department of the University Hospital of Palermo

Palermo, PA, Italy

Site Status: RECRUITING

Internal Medicine Division of the "Cervello-Villa Sofia" Hospital

Palermo, PA, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Pasquale Mansueto, MD

Role: CONTACT

pasquale.mansueto@unipa.it

+393477279879

Aurelio Seidita, MD

Role: CONTACT

aurelio.seidita@unipa.it

+393209150370

Facility Contacts

Pasquale Mansueto, MD

Role: primary

pasquale.mansueto@unipa.it

+39-091-6552884

Giuliana Guggino, MD

Role: primary

giuliana.guggino@unipa.it

Giulia Grasso, MD

Role: backup

giulia.grasso@unipa.it

Antonio Carroccio, MD

Role: primary

acarroccio@hotmail.com

+390916554815

References

Carroccio A, Giambalvo O, Blasca F, Iacobucci R, D'Alcamo A, Mansueto P. Self-Reported Non-Celiac Wheat Sensitivity in High School Students: Demographic and Clinical Characteristics. Nutrients. 2017 Jul 19;9(7):771. doi: 10.3390/nu9070771.

Reference Type: BACKGROUND

PMID: 28753927 (View on PubMed)

Carroccio A, Rini G, Mansueto P. Non-celiac wheat sensitivity is a more appropriate label than non-celiac gluten sensitivity. Gastroenterology. 2014 Jan;146(1):320-1. doi: 10.1053/j.gastro.2013.08.061. Epub 2013 Nov 22. No abstract available.

Reference Type: BACKGROUND

PMID: 24275240 (View on PubMed)

Carroccio A, Mansueto P, Iacono G, Soresi M, D'Alcamo A, Cavataio F, Brusca I, Florena AM, Ambrosiano G, Seidita A, Pirrone G, Rini GB. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol. 2012 Dec;107(12):1898-906; quiz 1907. doi: 10.1038/ajg.2012.236. Epub 2012 Jul 24.

Reference Type: BACKGROUND

PMID: 22825366 (View on PubMed)

Fasano S, Mauro D, Macaluso F, Xiao F, Zhao Y, Lu L, Guggino G, Ciccia F. Pathogenesis of primary Sjogren's syndrome beyond B lymphocytes. Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):315-323. Epub 2020 Oct 23.

Reference Type: BACKGROUND

PMID: 33095148 (View on PubMed)

Rizzo C, Grasso G, Destro Castaniti GM, Ciccia F, Guggino G. Primary Sjogren Syndrome: Focus on Innate Immune Cells and Inflammation. Vaccines (Basel). 2020 Jun 3;8(2):272. doi: 10.3390/vaccines8020272.

Reference Type: BACKGROUND

PMID: 32503132 (View on PubMed)

Rizzo C, La Barbera L, Lo Pizzo M, Ciccia F, Sireci G, Guggino G. Invariant NKT Cells and Rheumatic Disease: Focus on Primary Sjogren Syndrome. Int J Mol Sci. 2019 Oct 31;20(21):5435. doi: 10.3390/ijms20215435.

Reference Type: BACKGROUND

PMID: 31683641 (View on PubMed)

Other Identifiers

ACPM31

Identifier Type: -

Identifier Source: org_study_id